{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:14:52Z","timestamp":1790522092814,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T03:17:21Z","timestamp":1668568641000},"page":"560-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough"],"prefix":"10.1016","volume":"22","author":[{"given":"Iwona M.","family":"Pranke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Varilh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Faucon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Dreano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Karri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Bidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Namy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Taulan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.10.010_bib0001","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Sermet-gaudelus i. emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2022.10.010_bib0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2022.10.010_bib0003","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","article-title":"Leveraging rules of nonsense-mediated mRNA decay for genome engineering and personalized medicine","volume":"165","author":"Popp","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2022.10.010_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Ann Rev Genom Hum Genet"},{"key":"10.1016\/j.jcf.2022.10.010_bib0005","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jcf.2022.10.010_bib0006","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1074\/jbc.M113.533588","article-title":"Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases","volume":"289","author":"Shulman","year":"2014","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.jcf.2022.10.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.jcf.2022.10.010_bib0008","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2022.10.010_bib0009","first-page":"S1569","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","author":"de Poel","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.10.010_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study","volume":"5","author":"Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.10.010_bib0011","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2022.10.010_bib0012","article-title":"Correlating genotype with phenotype using CFTR-mediated whole-cell Cl- currents in human nasal epithelial cells","author":"Noel","year":"2021","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.jcf.2022.10.010_bib0013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-021-00740-z","article-title":"Long-term differentiating primary human airway epithelial cell cultures: how far are we","volume":"19","author":"Bukowy-Biery\u0142\u0142o","year":"2021","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jcf.2022.10.010_bib0014","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.bmcl.2012.08.107","article-title":"Identification of pyrimidine derivatives as hSMG-1 inhibitors","volume":"22","author":"Gopalsamy","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"10.1016\/j.jcf.2022.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.jcf.2022.10.010_bib0016","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jcf.2022.10.010_bib0017","doi-asserted-by":"crossref","unstructured":"Floquet C., Deforges J., Rousset J.P., Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011; 39(8):3350\u201362; PMID:21149266; doi:10.1093\/nar\/gkq1277.","DOI":"10.1093\/nar\/gkq1277"},{"issue":"3","key":"10.1016\/j.jcf.2022.10.010_bib0018","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/15476286.2017.1285480","article-title":"Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells","volume":"14","author":"Bidou","year":"2017","journal-title":"RNA Biol"},{"issue":"21","key":"10.1016\/j.jcf.2022.10.010_bib0019","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jcf.2022.10.010_bib0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jcf.2022.10.010_bib0021","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1165\/rcmb.2019-0291OC","article-title":"Novel correctors and potentiators enhance translational readthrough in CFTR nonsense mutations","volume":"64","author":"Sharma","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.jcf.2022.10.010_bib0022","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1164\/rccm.201808-1436LE","article-title":"Might brushed nasal cells be a surrogate for CFTR modulator clinical response?","volume":"199","author":"Pranke","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2022.10.010_bib0023","doi-asserted-by":"crossref","first-page":"00080","DOI":"10.1183\/23120541.00080-2017","article-title":"Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons","volume":"4","author":"Pranke","year":"2018","journal-title":"ERJ Open Res"},{"issue":"7","key":"10.1016\/j.jcf.2022.10.010_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.gt.3302211","article-title":"Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment","volume":"11","author":"Bidou","year":"2004","journal-title":"Gene Ther"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322013923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:44Z","timestamp":1761601664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322013923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199322013923"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}